menu search

PRTG / Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform
Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3.  The platform was acquired. Read More
Posted: Jul 20 2022, 16:07
Author Name: Benzinga
Views: 111626

PRTG News  

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

By Benzinga
July 20, 2022

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly o more_horizontal


Search within

Pages Search Results: